Pressure on Pyxis despite promising PYX-201 data

26 November 2024

Pyxis Oncology (Nasdaq: PYXS) has announced what look like encouraging early data from a Phase I trial of PYX-201, its lead antibody-drug conjugate (ADC), in solid tumors.

Investors took a different view, however, sending the company’s stock plummeting 45% on Thursday. A mixed outcome across indications may have added to concerns, with safety results also pointing to a limit on dosing levels.

PYX-201, which uniquely targets extradomain-B fibronectin (EDB+FN), is positioned as a potentially first-in-class ADC. Clinical activity was seen across six tumor types, including a 50% objective response rate in certain head and neck cancer patients.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology